COUMADIN TAB 1MG 1 MG
WARFARIN SODIUM : 1 MG · DIN 01918311 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: CANCELLED POST MARKET
What is COUMADIN TAB 1MG?
COUMADIN TAB 1MG 1 MG contains WARFARIN SODIUM : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 01918311, held by BRISTOL-MYERS SQUIBB CANADA, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jun-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COUMADIN TAB 1MG used for?
Prophylaxis/treatment of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization; adjunct in prophylaxis of systemic embolism after MI (stroke, reinfarction).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01918311 |
|---|---|
| Brand name | COUMADIN TAB 1MG |
| Generic / active ingredient | WARFARIN SODIUM : 1 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AA03 WARFARIN |
| AHFS class | 20:12.04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jun-2020 |
| Original market date | 1957-12-31 00:00:00 |
How is it administered?
Individualized dosage based on PT/INR. Usual maintenance dose is 2 to 10 mg daily. Monitor INR frequently during initiation and when changing other medications.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in provided text.
How is it supplied?
Not specified in provided text.
Contraindications
Pregnancy; haemorrhagic tendencies; recent/contemplated CNS or eye surgery; active GI/GU/respiratory ulceration; cerebral aneurysms; bacterial endocarditis; malignant hypertension.
Warnings and precautions
Major or fatal bleeding risk. Tissue necrosis/gangrene. Systemic atheroemboli (purple toe syndrome). Calciphylaxis. Narrow therapeutic index drug requiring regular INR monitoring.
What can be used instead?
Other Canadian products sharing ATC code B01AA03 WARFARIN. 16 of 60 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-WARFARIN | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02242924 |
| APO-WARFARIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02242929 |
| APO-WARFARIN | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02242925 |
| APO-WARFARIN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242926 |
| APO-WARFARIN | 3 MG | TABLET | APOTEX INC | MARKETED | DIN 02245618 |
| APO-WARFARIN | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02242927 |
| APO-WARFARIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242928 |
| TARO-WARFARIN | 1 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242680 |
| TARO-WARFARIN | 10 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242687 |
| TARO-WARFARIN | 2 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242681 |
Who else supplies WARFARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. WARFARIN appears in 2044 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.